Cephalon announced that the FDA has approved Treanda (bendamustine hydrochloride) for injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease. The American Cancer Society estimates that more than 15,000 new cases of the disease will be diagnosed in the US this year. Treanda will be available to physicians and patients in April, Cephalon said.
Novo Nordisk announced that the FDA has approved NovoLog (insulin aspart [rDNA origin] injection) for continuous subcutaneous insulin infusion (CSII) by external insulin pump in pediatric patients between the ages of 4 and 18 years. NovoLog is the first and only insulin analog approved for this use.
